Clinical Trial Update: Safety and Immunogenicity of CJCV2 With and Without ALFQ [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and immunogenicity of CJCV2 with and without the ALFQ adjuvant for Campylobacter infection; results were posted on 2026-01…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Campylobacter Infection

Drugs mentioned

• ALFQ (Adjuvant Lipid Formulation with QS-21)
• CJCV2

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Campylobacter Infection | Phase 1 | Status: COMPLETED | Results posted: 2026-01-30